Axium receives ACHC accreditation
LAKE MARY, Fla. — The Accreditation Commission for Health Care has accredited specialty pharmacy provider Axium Healthcare Pharmacy, Axium said Tuesday.
Axium said the accreditation was given for its headquarters in Florida and for sites in Mississippi and Puerto Rico. The ACHC was formed by home care and community-based providers with the goal of helping companies improve business operations and patient care quality. Organizations obtain accreditation by submitting to peer review of their internal policies, processes and patient care delivery, which are compared with national standards.
“Accreditation provides our patients, physicians, payers and manufacturers assurance of Axium delivering a high-quality, patient-focused care and personalized superior service,” Axium president and CEO Mark Montgomery said.
Citing safety concerns, Lilly suspends cancer drug trial
INDIANAPOLIS — Eli Lilly is suspending a late-stage clinical trial of a cancer drug amid safety concerns, the drug maker said Monday.
The company had been conducting a phase-3 trial of the pharmaceutical drug tasisulam as a second-line treatment for patients with melanoma whose cancer could not be removed or had spread to other parts of the body. Melanoma, the deadliest form of skin cancer, is diagnosed in 68,000 people in the Untied States every year, according to the American Cancer Society.
Trials of the drug in patients with leukemia, soft tissue sarcoma, breast, ovarian and kidney cancers will continue due to differences in dosing.
“We are thoroughly reviewing the clinical trial data to understand what modifications to the study protocol or dosing would be needed to improve patient safety on this trial,” said Richard Gaynor, Lilly VP oncology product development and medical affairs.
Regulatory approval application accepted for Exparel
PARSIPPANY, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a pain drug made by Pacira Pharmaceuticals, Pacira said Tuesday.
The drug maker submitted its application for the long-acting painkiller Exparel (bupivacaine) in September.
The drug is a topical medication for managing pain following surgery. The FDA expects to finish reviewing the application in July 2011.